Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Rheumatology · Immune-mediated necrotizing myopathy

Can statins cause dermatomyositis or myositis?

At a Glance

Statins do not cause dermatomyositis. However, they can trigger a rare, serious condition called immune-mediated necrotizing myopathy (IMNM) which mimics it. Unlike standard statin aches, IMNM causes progressive muscle weakness that requires immunosuppressive treatment even after stopping statins.

No, taking statins for your cholesterol does not cause dermatomyositis, which is a distinct autoimmune disease [1][2]. However, statins can trigger a very rare but serious condition called immune-mediated necrotizing myopathy (IMNM) (also known as statin-induced necrotizing myopathy) [3][4].

Because statin-induced IMNM causes severe muscle weakness, elevated muscle enzymes, and occasionally a skin rash, it is a major “mimic” of dermatomyositis [1][5]. This overlap in symptoms is why many patients understandably worry that their cholesterol medication caused their condition. However, classic dermatomyositis is uniquely characterized by its distinct skin rashes (like a purplish rash on the eyelids or scaly bumps on the knuckles) and different underlying causes.

Understanding Statin-Induced Necrotizing Myopathy

Millions of people take statins safely. Some individuals experience common, self-limiting muscle aches (toxic statin-associated myopathy) that typically resolve when the medication is stopped [6]. (Note: Never stop taking your prescribed heart or cholesterol medications without consulting your doctor).

Statin-induced IMNM is completely different. It is an autoimmune reaction where the immune system creates autoantibodies—proteins that mistakenly attack the body’s own tissues—specifically targeting an enzyme involved in cholesterol production called HMG-CoA reductase [3][7]. Unlike standard statin muscle aches, the muscle weakness in IMNM continues to progress and worsen even after you stop taking the statin [4][6].

How Doctors Tell the Difference

While statin-induced IMNM and dermatomyositis might look similar in the clinic due to the severe muscle weakness they both cause, they look very different under a microscope and in your bloodwork. Doctors primarily use three tools to distinguish them:

1. Blood Tests for Muscle Enzymes (Creatine Kinase)
When muscles are damaged, they release an enzyme called creatine kinase (CK) into the blood. While both conditions elevate CK levels, IMNM often causes exceptionally high CK levels, which can provide doctors with an early clinical clue [8][9].

2. Autoantibody Blood Tests
Myositis-specific antibodies are blood markers that help doctors identify exactly which type of muscle disease you have [10].

  • Statin-Induced IMNM: Patients typically test positive for anti-HMGCR antibodies [11][2].
  • Dermatomyositis: Patients usually test positive for completely different antibodies, such as anti-TIF1-gamma, anti-MDA5, or anti-Mi-2 [12][10].

3. Muscle Biopsies
A muscle biopsy is often the “gold standard” for confirming the diagnosis. Evaluating a small sample of muscle tissue under a microscope shows exactly how the muscle is being damaged [13].

  • Statin-Induced IMNM: A biopsy shows widespread necrosis (muscle cell death) with very little actual inflammation [14][15].
  • Dermatomyositis: A biopsy typically shows perifascicular atrophy (shrinkage of muscle fibers at the edges of the muscle bundle) and prominent primary inflammatory cells [16][17]. Biopsies for dermatomyositis also test positive for a specific protein marker called MxA, which is highly specific to dermatomyositis and not found in IMNM [18][19].

Why the Exact Diagnosis Matters

Getting a precise diagnosis between dermatomyositis and statin-induced IMNM is critical for your care plan.

First, while both diseases require long-term treatments to calm the immune system, the specific treatment protocols differ. Statin-induced IMNM often requires a very aggressive combination of strong immunosuppressive medications to stop the muscle destruction, because simply stopping the statin is not enough to halt the autoimmune response [6][20]. Classic dermatomyositis also requires immunosuppression (like corticosteroids), but the specific drug combinations and timelines are tailored to its unique inflammatory profile.

Second, classic dermatomyositis carries distinct long-term health risks depending on your specific antibodies. For example, certain dermatomyositis antibodies are associated with interstitial lung disease or an increased risk of hidden cancers (malignancies) [12][21]. Confirming exactly which condition you have tells your doctor which risks to watch out for. This is exactly why your care team will perform regular health screenings—so they can catch and treat any potential issues as early as possible.

Common questions in this guide

Can taking a statin for cholesterol cause dermatomyositis?
No, statins do not cause dermatomyositis, which is a completely distinct autoimmune disease. However, they can trigger a rare but serious condition called immune-mediated necrotizing myopathy (IMNM) that acts as a major mimic.
Will my muscle weakness go away if I stop taking my statin?
For common statin-induced muscle aches, symptoms usually improve when the medication is stopped. However, if you have developed statin-induced IMNM, stopping the drug is not enough to halt the autoimmune response, and muscle weakness will continue to progress without treatment.
How do doctors tell the difference between statin-induced myopathy and dermatomyositis?
Doctors primarily use three tools to tell them apart: creatine kinase blood tests, autoantibody blood tests, and muscle biopsies. Statin-induced IMNM typically tests positive for anti-HMGCR antibodies, while dermatomyositis presents with different antibodies and distinct skin rashes.
What does a positive anti-HMGCR antibody test mean?
A positive anti-HMGCR antibody test usually indicates statin-induced immune-mediated necrotizing myopathy. This means your immune system is mistakenly attacking an enzyme involved in cholesterol production, leading to severe and progressive muscle damage.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specific myositis antibody did I test positive for, and what does that mean for my prognosis?
  2. 2.Did my muscle biopsy show signs of 'necrosis' or 'perifascicular atrophy'?
  3. 3.Given my diagnosis, do I need to stop or change my current cholesterol medication?
  4. 4.What specific health screenings should we schedule to monitor for complications associated with my specific antibody profile?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

Related questions

Can Dermatomyositis Cause Difficulty Swallowing?Can You Have a Dermatomyositis Flare with Normal CK?Can You Have Dermatomyositis Without Muscle Weakness?Does Treating Underlying Cancer Improve Dermatomyositis?How Does the Dermatomyositis Rash Appear on Dark Skin?How Long is the Dermatomyositis Maintenance Phase?How to Manage Scanxiety During Dermatomyositis ScreeningsIs Dermatomyositis a Fatal Disease? Prognosis ExplainedWhat Are the Most Common Dermatomyositis Misdiagnoses?What Does Seronegative Dermatomyositis Mean?What is the Dermatomyositis Steroid Taper Schedule?Why Does UV Light Trigger Dermatomyositis Flares?Why Take Bactrim Without an Infection in Dermatomyositis?

References

References (21)
  1. 1

    Statin-associated anti-HMGCR immune-mediated necrotizing myopathy with dermatomyositis-like features: A case report.

    Lim D, Landon-Cardinal O, Ellezam B, et al.

    SAGE open medical case reports 2020; (8()):2050313X20984120 doi:10.1177/2050313X20984120.

    PMID: 33447390
  2. 2

    Anti-HMGCR myopathy overlaps with dermatomyositis-like rash: a distinct subtype of idiopathic inflammatory myopathy.

    Hou Y, Shao K, Yan Y, et al.

    Journal of neurology 2022; (269(1)):280-293 doi:10.1007/s00415-021-10621-7.

    PMID: 34021410
  3. 3

    Statin-Associated Autoimmune Myopathy.

    Mammen AL

    The New England journal of medicine 2016; (374(7)):664-9 doi:10.1056/NEJMra1515161.

    PMID: 26886523
  4. 4

    A tough pill to swallow: Two cases of statin-induced necrotizing autoimmune myopathy manifesting as dysphagia and transaminitis.

    Chaudhry H, Lin J, Atefi R, et al.

    SAGE open medical case reports 2023; (11()):2050313X221150583 doi:10.1177/2050313X221150583.

    PMID: 36686203
  5. 5

    Case report: Diagnostic clues for anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase myopathy in pediatric patients.

    Watanuki K, Koga H

    Frontiers in pediatrics 2023; (11()):1102539 doi:10.3389/fped.2023.1102539.

    PMID: 36994439
  6. 6

    Statin-Associated Autoimmune Myopathy: Review of the Literature.

    Barrons R

    Journal of pharmacy practice 2023; (36(2)):383-393 doi:10.1177/08971900211040291.

    PMID: 35707933
  7. 7

    From Studio to Rehab: A Debilitating Form of Anti-HMGCR Myopathy.

    Anim-Koranteng C, Akpoigbe O, Miller M, Averbukh Y

    Cureus 2023; (15(6)):e40825 doi:10.7759/cureus.40825.

    PMID: 37489210
  8. 8

    CD163+ macrophage density in perimysial connective tissue associated with prognosis in IMNM.

    Sun H, Wang ZY, Han Y, et al.

    Annals of clinical and translational neurology 2024; (11(5)):1267-1279 doi:10.1002/acn3.52065.

    PMID: 38651547
  9. 9

    Diffuse Large B-cell Lymphoma Complicated with Anti-3-hydroxy-3-methylglutaryl-Coenzyme A Reductase Immune-mediated Necrotizing Myopathy.

    Tokunaga Y, Akiyama M, Nakano K, et al.

    Internal medicine (Tokyo, Japan) 2025; (64(4)):589-595 doi:10.2169/internalmedicine.3880-24.

    PMID: 38987186
  10. 10

    The Utility of Myositis Specific Antibodies in Clinical Practice.

    Biddle K, Taylor MD, Linstead SE, Kiely PDW

    The journal of applied laboratory medicine 2022; (7(5)):1189-1201 doi:10.1093/jalm/jfac038.

    PMID: 35716140
  11. 11

    Persistent exanthema mainly on the trunk with pathologically dermal interstitial mucin as anti-HMGCR myopathy-associated skin rash: Case series.

    Liu Z, Cheng N, Zheng S, et al.

    The Journal of dermatology 2025; (52(6)):1083-1089 doi:10.1111/1346-8138.17717.

    PMID: 40152349
  12. 12

    Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis.

    Ceribelli A, Isailovic N, De Santis M, et al.

    Clinical rheumatology 2017; (36(2)):469-475 doi:10.1007/s10067-016-3453-0.

    PMID: 27761751
  13. 13

    Where are we moving in the classification of idiopathic inflammatory myopathies?

    Tanboon J, Uruha A, Stenzel W, Nishino I

    Current opinion in neurology 2020; (33(5)):590-603 doi:10.1097/WCO.0000000000000855.

    PMID: 32852298
  14. 14

    Integrated Diagnosis Project for Inflammatory Myopathies: An association between autoantibodies and muscle pathology.

    Suzuki S, Uruha A, Suzuki N, Nishino I

    Autoimmunity reviews 2017; (16(7)):693-700 doi:10.1016/j.autrev.2017.05.003.

    PMID: 28479486
  15. 15

    Statin-Induced Anti-HMGCR-Associated Myopathy.

    Basharat P, Lahouti AH, Paik JJ, et al.

    Journal of the American College of Cardiology 2016; (68(2)):234-5.

    PMID: 27386780
  16. 16

    Elevated Expression of ADAM10 in Skeletal Muscle of Patients with Idiopathic Inflammatory Myopathies Could Be Responsible for FNDC5/Irisin Unbalance.

    Zerlotin R, Fornaro M, Errede M, et al.

    International journal of molecular sciences 2023; (24(3)) doi:10.3390/ijms24032469.

    PMID: 36768791
  17. 17

    Idiopathic Inflammatory Myopathies.

    Salajegheh MK, Amato AA

    Continuum (Minneapolis, Minn.) 2025; (31(5)):1385-1408 doi:10.1212/cont.0000000000001617.

    PMID: 41037168
  18. 18

    Sarcoplasmic Myxovirus Resistance Protein A: A Study of Expression in Idiopathic Inflammatory Myopathy.

    Waisayarat J, Wongsuwan P, Tuntiseranee K, et al.

    Journal of inflammation research 2023; (16()):5417-5426 doi:10.2147/JIR.S433239.

    PMID: 38026261
  19. 19

    Diagnostic potential of sarcoplasmic myxovirus resistance protein A expression in subsets of dermatomyositis.

    Uruha A, Allenbach Y, Charuel JL, et al.

    Neuropathology and applied neurobiology 2019; (45(5)):513-522 doi:10.1111/nan.12519.

    PMID: 30267437
  20. 20

    Atorvastatin-Induced Necrotizing Myopathy and its Response to Combination Therapy.

    Boppana SH, Syed HA, Antwi-Amoabeng D, et al.

    Cureus 2021; (13(1)):e12957 doi:10.7759/cureus.12957.

    PMID: 33659112
  21. 21

    Characteristics and prognostic implications of peripheral blood lymphocyte subsets in patients with anti-MDA5 antibody positive dermatomyositis-interstitial lung disease.

    Ren FP, Chen Q, Yao SS, et al.

    BMC pulmonary medicine 2023; (23(1)):411 doi:10.1186/s12890-023-02706-y.

    PMID: 37898737

This information comparing statin-induced myopathy and dermatomyositis is for educational purposes only. Never stop taking your prescribed heart or cholesterol medications without consulting your doctor first.

Get notified when new evidence is published on Dermatomyositis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.